Skip to main content
Premium Trial:

Request an Annual Quote

Product Watch: EKF Diagnostics' PointMan DNA Enrichment Kits

Premium

EKF Diagnostics said this week that it will launch its PointMan DNA enrichment kits at the American Society for Clinical Oncology meeting later this month in Chicago.

The company is commercializing three kits to enrich mutations in BRAF, KRAS, and EGFR T790M genes associated with melanoma, colorectal, and lung cancers. According to the company, PointMan kits offer highly specific and ultra-sensitive enrichment of mutant genes in a background of wild-type genes that is "unmatched" by existing technologies.

PointMan is a real-time PCR technology that is highly efficient in amplifying a target sequence of interest while suppressing amplification of wild-type sequences. The kits can be used to enrich all mutant sequences within a gene of interest using a single set of reagents, as opposed to requiring a separate reagents set for each mutation.

This will be the first product introduction by EKF since it acquired 360 Genomics and established EKF Molecular Diagnostics in March.

Filed under

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.